You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

  • Technology appraisal guidance
  • Reference number: TA272
  • Published:  23 January 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Research recommendations coming out of this guidance

  • Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed. It noted that the vinflunine studies were the only studies in patients with transitional cell carcinoma of the urothelial tract whose disease had progressed after platinum-based chemotherapy. It was noted that there is a lack of evidence for the relative effectiveness of treatment options at this stage in the pathway of care. It is recommended that studies be undertaken to investigate the relative safety and efficacy of second-line treatments for transitional cell carcinoma of the urothelial tract, particularly randomised controlled trials.

Back to top